Clinical Trials Directory

Trials / Unknown

UnknownNCT05361161

Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Gang Wu · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, open-labelled study to evaluate the efficacy and safety of sequential transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy in the treatment of Initial unresectable gastric cancer.

Conditions

Interventions

TypeNameDescription
DRUGTransarterial ChemoembolizationArterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.

Timeline

Start date
2022-06-01
Primary completion
2022-12-01
Completion
2025-12-01
First posted
2022-05-04
Last updated
2022-05-24

Source: ClinicalTrials.gov record NCT05361161. Inclusion in this directory is not an endorsement.

Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC) (NCT05361161) · Clinical Trials Directory